WFA
NKTR icon

Wipfli Financial Advisors’s Nektar Therapeutics NKTR Stock Holding History

Wipfli Financial Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$10K Buy
+206
New +$12.3K ﹤0.01% 1847

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wipfli Financial Advisors's NKTR Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Nektar Therapeutics (NKTR) in Q3 2022: 206 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #1847 among its holdings.

230 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

  • Wipfli Financial Advisors held 206 shares of Nektar Therapeutics worth $10K as of Q3 2022.
  • Nektar Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Nektar Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1847 holding.
  • 230 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.